keyword
MENU ▼
Read by QxMD icon Read
search

T-Vec

keyword
https://www.readbyqxmd.com/read/30261620/the-current-status-and-future-prospects-of-oncolytic-viruses-in-clinical-trials-against-melanoma-glioma-pancreatic-and-breast-cancers
#1
REVIEW
Ibrahim Ragab Eissa, Itzel Bustos-Villalobos, Toru Ichinose, Shigeru Matsumura, Yoshinori Naoe, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Wu Zhiwen, Maki Tanaka, Hitoki Hasegawa, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera, Hideki Kasuya
Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic® ) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for melanoma treatment in 2015. Various oncolytic viruses (OVs), such as HF10 (Canerpaturev-C-REV) and CVA21 (CAVATAK), are now actively being developed in phase II as monotherapies, or in combination with immune checkpoint inhibitors against melanoma. Moreover, in glioma, several OVs have clearly demonstrated both safety and a promising efficacy in the phase I clinical trials...
September 26, 2018: Cancers
https://www.readbyqxmd.com/read/30211812/successful-treatment-with-intralesional-talimogene-laherparepvec-in-two-patients-with-immune-checkpoint-inhibitors-refractory-advanced-melanoma
#2
Teofila Seremet, Simon Planken, Julia K Schwarze, Yanina Jansen, Laura Vandeweerd, Robbe van den Begin, Ioannis Tsechelidis, Danielle Lienard, Véronique Del Marmol, Bart Neyns
Monoclonal antibodies that block the programmed death-1 (anti-PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint receptors (pembrolizumab, nivolumab, ipilimumab, or the combination of nivolumab with ipilimumab) are approved treatment option for patients with advanced melanoma. Over half of all patients are refractory to these immunotherapies and are in need of alternative or complementary treatment options. Talimogene laherparepvec (T-VEC) is a first-in-class intralesionally delivered oncolytic immunotherapy, which has proven efficacy in the treatment of advanced melanoma...
September 11, 2018: Melanoma Research
https://www.readbyqxmd.com/read/30145781/the-role-of-oncolytic-viruses-in-the-treatment-of-melanoma
#3
REVIEW
Claire-Audrey Y Bayan, Adriana T Lopez, Robyn D Gartrell, Kimberly M Komatsubara, Margaret Bogardus, Nisha Rao, Cynthia Chen, Thomas D Hart, Thomas Enzler, Emanuelle M Rizk, Jaya Sarin Pradhan, Douglas K Marks, Larisa J Geskin, Yvonne M Saenger
PURPOSE OF REVIEW: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma. RECENT FINDINGS: Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting...
August 25, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/30058393/combining-vaccines-and-immune-checkpoint-inhibitors-to-prime-expand-and-facilitate-effective-tumor-immunotherapy
#4
Julie M Collins, Jason M Redman, James L Gulley
Multiple immune checkpoint inhibitors (ICIs) that modulate immune cells in the periphery and the tumor microenvironment (TME) have been approved, as have the therapeutic cancer vaccines sipuleucel-T for metastatic castration-resistant prostate cancer and talimogene laherparepvec (T-VEC) for metastatic melanoma. These developments provide rationale for combining these modalities to improve response rates and durability of responses in a variety of cancers. Preclinical data have shown that vaccines can induce immune responses that turn a tumor from 'cold' to 'hot,' but vaccines do not appear to be highly active as monotherapy...
August 2018: Expert Review of Vaccines
https://www.readbyqxmd.com/read/30054925/panniculitis-in-a-patient-with-pathologic-complete-response-to-talimogene-laherparepvec-treatment-for-recurrent-in-transit-melanoma
#5
Thomas H Long, Michi M Shinohara, Zsolt B Argenyi, John A Thompson, Jennifer M Gardner
Talimogene laherparepvec (T-VEC) is a novel intralesional oncolytic genetically modified herpes simplex virus type 1 vector for the treatment of unresectable cutaneous, subcutaneous, and nodal melanoma. Although immunological therapies such as T-VEC offer therapeutic promise, they carry a risk of immune-related adverse events (irAEs), the full spectrum of which is incompletely understood. We report a 63-year-old previously healthy man with cutaneous melanoma of the right ankle and progressive right lower extremity in-transit metastases despite systemic therapy with immunomodulatory and molecularly targeted treatments...
July 27, 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29961183/combining-tumor-vaccination-and-oncolytic-viral-approaches-with-checkpoint-inhibitors-rationale-pre-clinical-experience-and-current-clinical-trials-in-malignant-melanoma
#6
REVIEW
Ludimila Cavalcante, Akansha Chowdhary, Jeffrey A Sosman, Sunandana Chandra
The field of tumor immunology has faced many complex challenges over the last century, but the approval of immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and anti-programmed cell death-1 [PD-1]/PD-ligand 1 [PD-L1]) and talimogene laherparepvec (T-VEC) for the treatment of metastatic melanoma have awakened a new wave of interest in cancer immunotherapy. Additionally, combinations of vaccines and oncolytic viral therapies with immune checkpoint inhibitors and other systemic agents seem to be promising synergistic strategies to further boost the immune response against cancer...
October 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29904022/designer-oncolytic-adenovirus-coming-of-age
#7
REVIEW
Alexander T Baker, Carmen Aguirre-Hernández, Gunnel Halldén, Alan L Parker
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virotherapy, especially in combination with immune-checkpoint inhibitors, the quest continues for a virus capable of specific tumour cell killing via systemic administration. One candidate is oncolytic adenovirus (Ad); it’s double stranded DNA genome is easily manipulated and a wide range of strategies and technologies have been employed to empower the vector with improved pharmacokinetics and tumour targeting ability...
June 14, 2018: Cancers
https://www.readbyqxmd.com/read/29896663/oncolytic-virotherapy-by-hsv
#8
Daisuke Watanabe, Fumi Goshima
Oncolytic virotherapy is a kind of antitumor therapy using viruses with natural or engineered tumor-selective replication to intentionally infect and kill tumor cells. An early clinical trial has been performed in the 1950s using wild-type and non-engineered in vitro-passaged virus strains and vaccine strains (first generation oncolytic viruses). Because of the advances in biotechnology and virology, the field of virotherapy has rapidly evolved over the past two decades and innovative recombinant selectivity-enhanced viruses (second generation oncolytic viruses)...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29765544/comparison-of-infectivity-and-spread-between-hsv-1-and-hsv-2-based-oncolytic-viruses-on-tumor-cells-with-different-receptor-expression-profiles
#9
Xinping Fu, Lihua Tao, Pin-Yi Wang, Timothy P Cripe, Xiaoliu Zhang
Herpes simplex virus (HSV) is one of the many viruses that have been modified or adapted for oncolytic purposes. There are two serotypes of HSV, HSV-1 and HSV-2. The majority of oncolytic HSVs, including T-VEC which has recently been approved by the US Food and Drug Administration (FDA) for clinical use in treating late stage melanoma patients, are derived from HSV-1. Recently, we and others have developed several HSV-2 based oncolytic viruses. During our in vitro characterization of oncolytic viruses developed from both serotypes (Baco-1 from HSV-1 and FusOn-H2 from HSV-2), we noticed there is a subpopulation of cancer cells in which both viruses could infect but only FusOn-H2 could spread from cell to cell on monolayers...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29764498/talimogene-laherparepvec-combined-with-anti-pd-1-based-immunotherapy-for-unresectable-stage-iii-iv-melanoma-a-case-series
#10
Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C Marcela Diaz-Montero, Brian Gastman
BACKGROUND: Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining checkpoint inhibitor therapy with T-VEC injection can lead to improved response rates for stage IIIB-IV melanoma patients. METHODS: We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or nivolumab) treated between June 2016 and August 2017 at the Cleveland Clinic with a median follow-up of 7 months (range: 4 to 13 months)...
May 16, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29622046/complete-intracranial-response-to-talimogene-laherparepvec-t-vec-pembrolizumab-and-whole-brain-radiotherapy-in-a-patient-with-melanoma-brain-metastases-refractory-to-dual-checkpoint-inhibition
#11
Zoë Blake, Douglas K Marks, Robyn D Gartrell, Thomas Hart, Patti Horton, Simon K Cheng, Bret Taback, Basil A Horst, Yvonne M Saenger
BACKGROUND: Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management of patients progressing on first-line immunotherapy remains challenging. Expanded treatment options with combination immunotherapy has demonstrated efficacy in patients previously unresponsive to single agent or alternative combination therapy. CASE PRESENTATION: We describe the case of a patient with diffusely metastatic melanoma, including brain metastases, who, despite being treated with stereotactic radiosurgery and dual CTLA-4/PD-1 blockade (ipilimumab/nivolumab), developed systemic disease progression and innumerable brain metastases...
April 6, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29557682/pharmacokinetic-drug-evaluation-of-talimogene-laherparepvec-for-the-treatment-of-advanced-melanoma
#12
REVIEW
Erin E Burke, Jonathan S Zager
Current treatment of advanced melanoma is rapidly changing with the introduction of new and effective therapies including systemic as well as locoregional therapies. An example of one such locoregional therapy is intralesional injection with talimogene laherparepvec (T-VEC). Areas covered: T-VEC has been shown in a number of studies to be an effective treatment for patients with stage IIIB, IIIC and IVM1a melanoma. In this article the effectiveness, pharmacokinetics and safety profile of T-VEC is reviewed. Additionally, new research looking at combinations of T-VEC and systemic immunotherapies is reviewed...
April 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29464075/interleukin-8-activity-influences-the-efficacy-of-adenoviral-oncolytic-immunotherapy-in-cancer-patients
#13
Kristian Taipale, Siri Tähtinen, Riikka Havunen, Anniina Koski, Ilkka Liikanen, Päivi Pakarinen, Riitta Koivisto-Korander, Matti Kankainen, Timo Joensuu, Anna Kanerva, Akseli Hemminki
After the landmark approval of T-VEC, oncolytic viruses are finding their way to the clinics. However, response rates have still room for improvement, and unfortunately there are currently no available markers to predict responses for oncolytic immunotherapy. Interleukin 8 (IL-8) production is upregulated in many cancers and it also connects to several pathways that have been shown to impair the efficacy of adenoviral immunotherapy. We studied the role of IL-8 in 103 cancer patients treated with oncolytic adenoviruses...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29383039/diverse-cutaneous-adverse-eruptions-caused-by-anti-programmed-cell-death-1-pd-1-and-anti-programmed-cell-death-ligand-1-pd-l1-immunotherapies-clinical-features-and-management
#14
John Shen, Jason Chang, Melody Mendenhall, Grace Cherry, Jonathan W Goldman, Rajan P Kulkarni
Background: The anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies have shown exceptional activity in many cancers. However, these immunotherapies can also result in diverse adverse cutaneous eruptions that need to be better characterized for ongoing management. The objective was to provide clinical and histopathologic descriptions of the variety of cutaneous adverse events seen in patients who received anti-PD-1/PD-L1 treatment and discuss their management...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29344272/cancer-vaccine-learning-lessons-from-immune-checkpoint-inhibitors
#15
REVIEW
ZhenLong Ye, Qiming Qian, HuaJun Jin, QiJun Qian
Cancer vaccines have been exclusively studied all through the past decades, and have made exceptional achievements in cancer treatment. Few cancer vaccines have been approved by the US Food and Drug Administration (FDA), for instance, Provenge, which was approved for the treatment of prostate carcinoma in 2012. Moreover, more recently, T-VEC got approval for the treatment of melanoma. While, the overall therapeutic effects of cancer vaccines have been taken into consideration as below expectations, low antigenicity of targeting antigen and tumor heterogeneity are the two key limiting barriers encountered by the cancer vaccines...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29179583/oncolytic-viruses-for-tumor-precision-imaging-and-radiotherapy
#16
Zi J Wu, Feng R Tang, Zhao-Wu Ma, Xiao-Chun Peng, Ying Xiang, Yanling Zhang, Jingbo Kang, Jiafu Ji, Xiao Q Liu, Xian-Wang Wang, Hong-Wu Xin, Bo X Ren
In 2003 in China, Peng et al. invented the recombinant adenovirus expressing p53 (Gendicine) for clinical tumor virotherapy. This was the first clinically approved gene therapy and tumor virotherapy drug in the world. An oncolytic herpes simplex virus expressing granulocyte-macrophage colony-stimulating factor (Talimogene laherparepvec) was approved for melanoma treatment in the United States in 2015. Since then, oncolytic viruses have been attracting more and more attention in the field of oncology, and may become novel significant modalities of tumor precision imaging and radiotherapy after further improvement...
February 2018: Human Gene Therapy
https://www.readbyqxmd.com/read/29157300/prospects-for-combined-use-of-oncolytic-viruses-and-car-t-cells
#17
REVIEW
Adam Ajina, John Maher
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid tumours has proved far less successful...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28945708/safe-and-effective-standards-of-care-supporting-the-administration-of-t-vec-for-patients-with-advanced-melanoma-in-the-outpatient-oncology-setting
#18
Lisa M Wall, Abigail Baldwin-Medsker
BACKGROUND: Talimogene laherparepvec (T-VEC) is the first oncolytic virus (OV) to demonstrate therapeutic benefit for the treatment of advanced melanoma. As a live virus, the use of T-VEC in medical and surgical outpatient clinics posed challenges. 
. OBJECTIVES: The purpose of this article is to describe the challenges faced when introducing an OV treatment into outpatient clinics and the processes implemented to ensure safety for patients, caregivers, and staff across the care continuum...
October 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28870120/virotherapy-research-in-germany-from-engineering-to-translation
#19
REVIEW
Guy Ungerechts, Christine E Engeland, Christian J Buchholz, Jürgen Eberle, Henry Fechner, Karsten Geletneky, Per Sonne Holm, Florian Kreppel, Florian Kühnel, Karl Sebastian Lang, Mathias F Leber, Antonio Marchini, Markus Moehler, Michael D Mühlebach, Jean Rommelaere, Christoph Springfeld, Ulrich M Lauer, Dirk M Nettelbeck
Virotherapy is a unique modality for the treatment of cancer with oncolytic viruses (OVs) that selectively infect and lyse tumor cells, spread within tumors, and activate anti-tumor immunity. Various viruses are being developed as OVs preclinically and clinically, several of them engineered to encode therapeutic proteins for tumor-targeted gene therapy. Scientists and clinicians in German academia have made significant contributions to OV research and development, which are highlighted in this review paper...
October 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/28738050/intralesional-therapy-consensus-statements-for-best-practices-in-administration-from-the-melanoma-nursing-initiative
#20
Virginia Seery
BACKGROUND: Talimogene laherparepvec (T-VEC) is the first intralesional therapy for melanoma approved by the U.S. Food and Drug Administration. This oncolytic viral immunotherapy has improved outcomes for patients with locoregional recurrent melanoma and is showing promise in combination with systemic therapies. 
. OBJECTIVES: This article aims to provide oncology nurses with expert guidance on best practices in incorporating intralesional therapy for patients diagnosed with melanoma in practice...
August 1, 2017: Clinical Journal of Oncology Nursing
keyword
keyword
109513
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"